Welcome to Drug and Alcohol Treatment
| ||
Drug Treatment Thrombocytopenia Article
This is a selection made from among articles on Drug Treatment Thrombocytopenia. For a permanent link to this article, or to bookmark it for future reading, click here.
Signs and Symptoms of Drug Abuse
from: Drug abuse, involves the excessive and repeated use of a substance to escape reality to produce pleasure despite its destructive effects. The substances abused can be illegal drugs such as opium, cocaine, marijuana and their derivatives or legal substances used improperly, such as prescription drugs and inhalants like nail polish or gasoline.Drug addiction can be physical, psychological, or both. Physical dependence refers to the physiological effects of drug use. On the other hand, using a drug to numb unpleasant feelings, to relax, or to satisfy cravings are examples of psychological addiction. Physical addiction is characterized by ‘tolerance’ - the need for increasingly larger doses in order to achieve the initial effect and withdrawal symptoms when the user stops.
Signs and Symptoms of Drug Abuse: -
The more drug use begins to affect and control a person's life, the more likely it is that he or she has a drug problem. Drug abusers often try to conceal their symptoms and downplay their problem. However, there are a number of warning signs you can look for:
· Engaging in secretive or suspicious behaviors, such as making frequent trips to the restroom, basement, or other isolated areas where drug use would be undisturbed.
· Talking incoherently or making inappropriate remarks.
· Sudden changes in work or school attendance and quality of work or grades.
· Talking about drugs all the time and pressuring others to use.
· Angry outbursts, mood swings, irritability, manic behavior, or overall attitude change.
· Expressing feelings of exhaustion, depression, and hopelessness.
· Deterioration of physical appearance and grooming.
· Frequently borrowing money, selling possessions, or stealing items from employer, home, or school.
· No longer spending time with friends who do not use drugs and/or associating with known users.
The path to drug addiction begins with the act of taking drugs. Compulsive, drug craving, seeking, and use that persist even in the face of negative consequences characterize drug addiction. It is easier to prevent and stop drug addiction during the initial stages before a person becomes compulsively addicted to drugs.
About Author
DrugAlcoholTest.com is an online store offering Drug Test and drug screening products in several formats including blood, urine and oral drug test kits. These drug-testing kits can be used discreetly for at home drug test or for random employee Drug Testing . Some of the popular products are Marijuana Drug Test, Breathalyzer and Saliva Drug Test Products.
Source: ArticleTrader.com
Drug Treatment Thrombocytopenia Specific links
Drug Treatment Thrombocytopenia News
Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting
WOODCLIFF LAKE, N.J., May 17, 2012 /PRNewswire/ --Â Eisai announced today that 15 abstracts highlighting new study results will be presented during the 48 th Annual Meeting of the American Society of Clinical ...
Read more...Pfizer And Protalix BioTherapeutics Announce FDA Approval Of ELELYSO™ (taliglucerase alfa) For The Treatment Of ...
NEW YORK & CARMIEL, Israel--(BUSINESS WIRE)--Pfizer Inc.(NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved ELELYSO™ (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease. ELELYSO ...
Read more...Pfizer Provides Topline Results From Phase 3 Study Of Torisel® As Second-Line Treatment In Advanced Renal Cell ...
Pfizer Inc announced today that the Phase 3 INTORSECT study, evaluating TORISEL® in patients with advanced renal cell carcinoma whose disease had progressed on or after SUTENT® therapy, did not meet the primary endpoint of prolonging progression free survival when compared to sorafenib.
Read more...Press Release
Pfizer Inc.(NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved ELELYSO™ (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease.
Read more...Seattle Genetics Announces Data from Investigator Trial of ADCETRIS™ in Relapsed Cutaneous T-Cell Lymphoma
Seattle Genetics, Inc. today announced that interim results from an investigator-sponsored phase II clinical trial of ADCETRIS in patients with relapsed cutaneous T-cell lymphoma were presented at the Society for Investigative Dermatology annual meeting being held May 9-12, 2012 in Raleigh, NC.
Read more...New England Journal of Medicine Reports on Three Phase III REVLIMID® (lenalidomide) Trials in Patients with Newly ...
Celgene International Sà rl, a subsidiary of Celgene Corporation , today announced that results from three phase III studies evaluating the use of continuous REVLIMID® treatment in newly diagnosed multiple myeloma patients or maintenance treatment with lenalidomide following autologous stem cell transplant were published online in the May 10, 2012 edition of the New England Journal of Medicine.
Read more...VIVITROL® Data to be Presented at Upcoming American Psychiatric Association Annual Meeting
DUBLIN--(BUSINESSWIRE)-- — Highlighted Data Include Long-Term Safety, Efficacy and Cost-Effectiveness Analyses of VIVITROL in Treatment of Alcohol and Opioid Dependence — Alkermes plc (NASDAQ: ALKS) today ...
Read more...Millennium and Seattle Genetics Initiate Global Phase 3 Trial of ADCETRIS™ in Patients with CD30-Expressing Relapsed ...
Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc. , today announced the initiation of an international pivotal phase 3 clinical trial evaluating ADCETRIS in patients with CD30-expressing cutaneous T-cell lymphoma who received at least one prior systemic therapy.
Read more...Pfizer Announces FDA Approval Of Elelyso For Treatment Of Type 1 Gaucher Disease
Pfizer Announces FDA Approval Of Elelyso For Treatment Of Type 1 Gaucher Disease
Read more...New Data from Bristol-Myers Squibb Oncology Portfolio to be Presented at 2012 American Society of Clinical Oncology ...
Bristol-Myers Squibb Company today announced that new data on its approved and investigational oncology compounds will be featured in ten oral presentations at the 48th Annual Meeting of the American Society of Clinical Oncology in Chicago from June 1-5.
Read more...